Hims & Hers Health (NYSE:HIMS) Stock: Insider Soleil Boughton Sells 3,461 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,461 shares of the company’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $29.06, for a total value of $100,576.66. Following the completion of the transaction, the insider owned 297,348 shares of the company’s stock, valued at $8,640,932.88. This trade represents a 1.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, September 30th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.17, for a total value of $100,957.37.
• On Wednesday, September 16th, Soleil Boughton sold 6,236 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.86, for a total value of $173,734.96.
• On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.33, for a total value of $97,965.14.
• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05.

Hims & Hers Health Stock Performance

HIMS traded up $1.81 during trading on Thursday, hitting $29.53. 15,936,884 shares of the company traded hands, compared to its average volume of 23,095,879. The firm has a market cap of $6.89 billion, a P/E ratio of -46.88 and a beta of 2.44. The stock’s fifty day moving average is $29.32 and its 200 day moving average is $28.66. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $63.63.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%. The company had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter last year, the business posted $0.17 EPS. The business’s quarterly revenue was up 38.2% on a year-over-year basis. As a group, equities analysts predict that Hims & Hers Health, Inc. will post -0.16 EPS for the current fiscal year.

Analysts Set New Price Targets

HIMS has been the subject of a number of research reports. Truist Financial increased their target price on shares of Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a research report on Monday, August 24th. Needham & Company LLC lifted their price target on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Wall Street Zen raised shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $32.43.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers launched its Hers women’s-health platform in Australia following its acquisition of Eucalyptus, a deal valued at approximately $1.15 billion. The rollout expands Hims’ geographic reach and adds offerings in weight management, hormonal health and hair regrowth, potentially creating new long-term revenue opportunities. Hims & Hers Launches Hers in Australia
• Neutral Sentiment: Multiple law firms issued substantially similar notices reminding investors that November 2, 2026 is the deadline to seek lead-plaintiff status in a securities class action covering purchases made from August 4, 2025, through July 29, 2026. The repeated announcements largely publicize the existing case rather than represent separate lawsuits or new company developments. Kaplan Fox HIMS Class Action Notice
• Negative Sentiment: The securities litigation and FTC-related allegations are the main bearish catalyst. Investors face uncertainty over potential legal costs, regulatory remedies, reputational damage and the effect on customer growth or operating practices. The legal overhang may continue to increase volatility until the allegations are resolved. Hims & Hers Faces Securities Fraud Class Action

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its holdings in Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after purchasing an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its position in Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after purchasing an additional 319 shares during the period. GK Wealth Management LLC purchased a new position in shares of Hims & Hers Health in the third quarter worth about $37,000. Compass Financial Management LLC purchased a new position in shares of Hims & Hers Health in the second quarter worth about $50,000. Finally, Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new position in shares of Hims & Hers Health in the fourth quarter worth about $80,000. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.